RxDoctor Payments DataLook up a doctor →

Chandan Lad, MD

Family Medicine · Tulsa, OKNPI 1164409025

Payments from drug & device makers

$22,290in general payments, 2019–2025

Across 1,516 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Pfizer$2K
  • Lilly USA, LLC$2K
  • AbbVie$2K
  • GSK$2K
  • plus $10K from 48 others

What the payments were for

  • Food & beverage$22,283100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,290 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$22,351
Medicare patients
100
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$34,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$29,485
OzempicSemaglutide12$11,041
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,056
Atorvastatin Calcium218$6,800
Montelukast Sodium150$5,763
Rosuvastatin Calcium78$3,814
Omeprazole123$3,308
Albuterol Sulfate HfaAlbuterol Sulfate78$3,253
Amlodipine Besylate259$3,088
Gabapentin181$2,934
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,879
Pravastatin Sodium58$2,607
Fluticasone Propionate71$2,012
Losartan Potassium121$1,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,053$34,52232 claims
GSKTrelegy Ellipta$1,596$29,48538 claims
Novo NordiskOzempic$2,336$11,04112 claims
AstraZenecaBreztri Aerosphere$2,716$9,05615 claims
Almatica Pharma LLCSertraline Hcl$99$61241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →